A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Authors
Keywords
Dichloroacetate, Phase 1, Cancer, Recommended phase 2 dose
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 3, Pages 603-610
Publisher
Springer Nature
Online
2015-03-12
DOI
10.1007/s10637-015-0221-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation
- (2014) Gopinath Sutendra et al. CELL
- Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
- (2014) Edward B. Garon et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
- (2014) D. Ross Camidge et al. Journal of Thoracic Oncology
- Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism
- (2013) Yi Xuan et al. EXPERIMENTAL CELL RESEARCH
- Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
- (2013) E. M. Dunbar et al. INVESTIGATIONAL NEW DRUGS
- Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
- (2013) Krishan Kumar et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Long-term safety of dichloroacetate in congenital lactic acidosis
- (2013) Monica Abdelmalak et al. MOLECULAR GENETICS AND METABOLISM
- Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
- (2013) Gopinath Sutendra et al. Frontiers in Oncology
- Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
- (2012) Y-C Shen et al. BRITISH JOURNAL OF CANCER
- Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer
- (2012) G Sutendra et al. ONCOGENE
- Combination of Sulindac and Dichloroacetate Kills Cancer Cells via Oxidative Damage
- (2012) Kasirajan Ayyanathan et al. PLoS One
- Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer
- (2011) Jingtao Tong et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Human Polymorphisms in the Glutathione Transferase Zeta 1/Maleylacetoacetate Isomerase Gene Influence the Toxicokinetics of Dichloroacetate
- (2011) Albert L. Shroads et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism
- (2011) Taro Hitosugi et al. MOLECULAR CELL
- Metabolic Modulation of Glioblastoma with Dichloroacetate
- (2010) E. D. Michelakis et al. Science Translational Medicine
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
- (2009) Shanta Dhar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Dichloroacetate (DCA) sensitizes both wild‐type and over expressingBcl‐2prostate cancer cells in vitro to radiation
- (2008) Wengang Cao et al. PROSTATE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More